COEP NASDAQ
Wexford, PA 15090
US
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| BSG Series CM, LLC | 0 | — | 2026-04-24 | |
| Cogley Brian | A-Award | 12,500 | — | 2026-02-11 |
| Cogley Brian | M-Exempt | 10,000 | $10.56 | 2026-02-11 |
| Deschamps Philippe | M-Exempt | 5,700 | $10.56 | 2026-02-11 |
| Deschamps Philippe | A-Award | 3,250 | — | 2026-02-11 |